Cambrex, Cytori to provide adipose-derived stem-cell research products

By Elaine Rigoli

Tampa, Fla., June 13 - Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corp. and Cytori Therapeutics have entered into a strategic marketing agreement to provide adipose-derived stem cell products globally for use in basic and translational bioresearch.

Under the agreement, Cambrex will manufacture and market products to the research community under the co-exclusive license from Cytori.

In return for the license, Cytori will receive royalties on all cells, media and related future research products based upon the licensed technology, according to a news release.

Adipose tissue is known to contain a rich population of stem and progenitor cells that have been shown to possess significant regenerative properties in multiple clinical disciplines.

Cytori is San Diego-based pharmaceutical company.

Cambrex is a global pharmaceutical company based in East Rutherford, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.